Meetings - The ASCO Post

Adjuvant radiation therapy following radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings f...

Prostate Cancer

By The ASCO Post Staff / September 2025 / 2025 ASTRO Annual Meeting

PAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide

Assessment with a genomic test could help predict which patients with recurrent prostate cancer are most likely to benefit from the addition of hormonal therapy to radiation following prostatectomy, a...

Prostate Cancer

By The ASCO Post Staff / September 2025 / 2025 ASTRO Annual Meeting

Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease

A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutica...

2025 ASTRO Annual Meeting

Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer

PAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide

Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease

Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced MIBC

FDA Approves Ropeginterferon alfa-2b-njft for Adults With Polycythemia Vera

Interferon-Alfa vs Hydroxyurea in Previously Untreated Patients With Polycythemia Vera and Essential Thrombocythemia

Ruxolitinib for Patients With Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide

FDA Approves Momelotinib for Patients With Myelofibrosis and Anemia